MA42303A - Formulations pharmaceutiques - Google Patents

Formulations pharmaceutiques

Info

Publication number
MA42303A
MA42303A MA042303A MA42303A MA42303A MA 42303 A MA42303 A MA 42303A MA 042303 A MA042303 A MA 042303A MA 42303 A MA42303 A MA 42303A MA 42303 A MA42303 A MA 42303A
Authority
MA
Morocco
Prior art keywords
pharmaceutical formulations
formulations
pharmaceutical
Prior art date
Application number
MA042303A
Other languages
English (en)
Inventor
Joanna Koziara
Diana Sperger
Original Assignee
Gilead Sciences Inc
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc, Janssen Sciences Ireland Uc filed Critical Gilead Sciences Inc
Publication of MA42303A publication Critical patent/MA42303A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA042303A 2015-06-30 2016-06-28 Formulations pharmaceutiques MA42303A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562187102P 2015-06-30 2015-06-30
US201662296524P 2016-02-17 2016-02-17

Publications (1)

Publication Number Publication Date
MA42303A true MA42303A (fr) 2018-05-09

Family

ID=56413867

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042303A MA42303A (fr) 2015-06-30 2016-06-28 Formulations pharmaceutiques

Country Status (16)

Country Link
US (1) US20170027967A1 (fr)
EP (1) EP3316869A1 (fr)
JP (2) JP2018519325A (fr)
KR (2) KR20200037880A (fr)
CN (1) CN107921003A (fr)
AU (1) AU2016285916B9 (fr)
BR (1) BR112017028140A2 (fr)
CA (1) CA2921336A1 (fr)
EA (1) EA201792591A1 (fr)
HK (2) HK1252156A1 (fr)
IL (1) IL256491A (fr)
MA (1) MA42303A (fr)
MX (1) MX2017016802A (fr)
NZ (1) NZ738524A (fr)
SG (1) SG10201912530XA (fr)
WO (1) WO2017004012A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2926068T3 (es) 2012-12-21 2022-10-21 Gilead Sciences Inc Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico
RS62434B1 (sr) 2014-12-26 2021-11-30 Univ Emory Antivirusni n4-hidroksicitidin derivati
SG11201802983TA (en) 2015-11-09 2018-05-30 Gilead Sciences Inc Therapeutic compositions for treatment of human immunodeficiency virus
WO2018064654A1 (fr) * 2016-10-01 2018-04-05 James Smeeding Compositions pharmaceutiques comprenant une statine et un cannabinoïde et leurs utilisations
TWI784370B (zh) 2017-01-31 2022-11-21 美商基利科學股份有限公司 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
CN111372592A (zh) 2017-12-07 2020-07-03 埃默里大学 N4-羟基胞苷及衍生物和与其相关的抗病毒用途
MX2020009856A (es) * 2018-03-25 2020-10-08 Biohaven Pharm Holding Co Ltd Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp).
KR102281373B1 (ko) 2018-04-26 2021-07-22 주식회사 엘지에너지솔루션 고체 전해질 전지용 양극 및 그를 포함하는 고체 전해질 전지
KR102016952B1 (ko) * 2019-04-19 2019-09-02 유니셀랩 주식회사 신규한 결정형 형태의 항바이러스제 및 이의 제조방법
US20210000823A1 (en) * 2019-07-03 2021-01-07 Janssen Sciences Ireland Unlimited Company Methods of treating hiv
CN117338733B (zh) * 2023-10-12 2024-05-28 杭州和泽坤元药业有限公司 一种富马酸替诺福韦二吡呋酯片及其制备工艺

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME01980B (fr) * 2010-11-19 2015-05-20 Gilead Sciences Inc Compositions thérapeutiques comprenant un hydrochlorure de rilpivirine et un fumarate de ténofovir disoproxil
KR20140119177A (ko) * 2012-02-03 2014-10-08 길리애드 사이언시즈, 인코포레이티드 바이러스 감염의 치료에 사용하기 위한 테노포비르 알라페나미드 헤미푸마레이트 및 코비시스타트를 포함하는 조합 요법
JP2016528240A (ja) * 2013-08-14 2016-09-15 ラシオファルム ゲーエムベーハー ドルテグラビル、エムトリシタビン及びテノホビルの医薬コンビネーションを有する医薬

Also Published As

Publication number Publication date
HK1252156A1 (zh) 2019-05-17
HK1254343A1 (zh) 2019-07-19
AU2016285916B9 (en) 2019-04-04
WO2017004012A1 (fr) 2017-01-05
US20170027967A1 (en) 2017-02-02
JP2018519325A (ja) 2018-07-19
CN107921003A (zh) 2018-04-17
CA2921336A1 (fr) 2016-12-30
KR20200037880A (ko) 2020-04-09
BR112017028140A2 (pt) 2018-08-28
EP3316869A1 (fr) 2018-05-09
MX2017016802A (es) 2018-09-06
JP2019116514A (ja) 2019-07-18
AU2016285916A1 (en) 2018-01-18
EA201792591A1 (ru) 2018-06-29
NZ738524A (en) 2019-02-22
KR20180048584A (ko) 2018-05-10
SG10201912530XA (en) 2020-02-27
IL256491A (en) 2018-02-28
AU2016285916B2 (en) 2019-03-07

Similar Documents

Publication Publication Date Title
MA50541A (fr) Formulations pharmaceutiques
DK3529248T3 (da) Farmaceutiske sammensætninger
DK3089741T3 (da) Farmaceutiske sammensætninger omfattende azd9291
MA42303A (fr) Formulations pharmaceutiques
MA46867A (fr) Formulations pharmaceutiques
DK3634377T3 (da) Farmaceutisk formulering
MA54716A (fr) Réduction de la viscosité de formulations pharmaceutiques
MA45187A (fr) Combinaisons pharmaceutiques
DK3199161T3 (da) Farmaceutisk præparat
MA44987A (fr) Formulations de médicaments améliorées
MA49837A (fr) Compositions pharmaceutiques
DK3583943T3 (da) Farmaceutisk sammensætning
DK3191085T3 (da) Misbrugsresistente farmaceutiske sammensætninger
DK3313370T3 (da) Oftalmologisk farmaceutisk sammensætning
ZA201707094B (en) Pharmaceutical formulations
ES2981002T3 (es) Formulación farmacéutica
DK3601277T3 (da) Farmaceutisk formulering
DK3256138T3 (da) Farmaceutiske sammensætninger omfattende meloxicam
DK3288967T3 (da) Farmaceutisk forbindelse
TR201503831A2 (tr) Antimipertansif kombinasyon formülasyonları
DK3089740T3 (da) Farmaceutisk sammensætning
MA49625A (fr) Compositions pharmaceutiques
DK3481370T3 (da) Farmaceutisk sammensætning omfattende benzydamin
DK3558261T3 (da) Farmaceutiske sammensætninger omfattende safinamid
MA42111A (fr) Compositions pharmaceutiques topiques